Eloxx Pharmaceuticals (ELOX) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $48.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | IMA |
|---|---|---|
| Share price | $15.18 | $4.26 |
| Market cap | $61.27M | $48.45M |
| 1-day change | +2.02% | -7.59% |
| YTD return | — | -33.19% |
| 1-year return | — | -44.72% |
| 5-year return | — | -96.83% |
| P/E ratio (TTM) | 4.31 | — |
| EPS (TTM) | $3.52 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $9.10 |
| 52-week low | $8.20 | $3.94 |
| Distance from 52-week high | -35.13% | -53.19% |
| Analyst consensus | none | none |
| Avg. price target upside | +151.98% | +322.54% |
| Average volume | 46.44K | 12.81K |
| Shares outstanding | 4.04M | 11.37M |
| Employees | 10 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Healthcare · Biotechnology · 10 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Healthcare · Biotechnology · 18 employees
ELOX vs IMA FAQ
Which is bigger, Eloxx Pharmaceuticals or ImageneBio?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $48.45M for ImageneBio (IMA).
Are Eloxx Pharmaceuticals and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.